Oxford Nanopore said Norway’s MATRIX program began rolling out rapid nanopore sequencing for central nervous system tumor classification across the country’s public healthcare infrastructure. The MATRIX rollout is being integrated into Norway’s National Infrastructure for Precision Diagnostics (InPreD), with a Phase 1 evaluation of 50 CNS tumor samples reported as meeting the program’s validation goals. Oxford Nanopore stated it observed strong agreement between nanopore-based CNS tumor classification and established diagnostic methods, supporting a Phase 2 rollout beginning at Oslo University Hospital, Haukeland University Hospital and St. Olavs Hospital. The program includes training, LIS integration, bioinformatics validation, diagnostic pathway design and logistics support. Oxford Nanopore also said MATRIX plans to expand the assay into somatic and germline variant detection, copy number variation benchmarking, single-cell transcriptomics and genome-wide methylation, aiming to incorporate multiomics into existing workflows ahead of EU IVDR documentation by the end of the year.